A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Acquired Bacterial Pneumonia

Trial Profile

A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Acquired Bacterial Pneumonia

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Lefamulin (Primary) ; Lefamulin (Primary) ; Linezolid; Linezolid; Moxifloxacin; Moxifloxacin
  • Indications Community-acquired pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms LEAP; LEAP 1
  • Sponsors Nabriva Therapeutics
  • Most Recent Events

    • 07 Aug 2017 According to a Nabriva Therapeutics media release, the company expects top-line data from the study in September 2017.
    • 31 May 2017 This trial has been completed in Bulgaria (end date: 2017-05-12), according to European Clinical Trials Database record.
    • 30 May 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top